Business
Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced a scientific collaboration with Unravel Biosciences, Inc., a clinical-stage therapeutics company established to advance drugs for complex diseases through its Predictable Medicine™ platform. This partnership aims to accelerate the discovery and optimization of a first-in-class small-mol
About this update from Evogene Ltd.
[{"type":"text","content":"Partnership addresses the unmet need for remyelination therapies for multiple sclerosis and other demyelinating conditions by leveraging generative chemistry design and patient-derived predictive platform","length":204,"tagName":"p"},{"type":"text","content":"REHOVOT, Israel and BOSTON, January 7, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced a scientific collaboration with Unravel Biosciences, Inc., a clinical-stage therapeutics company established to advance drugs for complex diseases through its Predictable Medicine™ platform. This partnership aims to accelerate the discovery and optimization of a first-in-class small-molecule therapeutic capable of restoring myelin and reversing neurological damage in demyelinating diseases.","length":671,"tagName":"p"},{"type":"image","alt":"Evogene Logo","displaySize":"","headline":null,"caption":"Evogene Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":230,"url":"https://media.zenfs.com/en/prnewswire.com/cd018876f2283f57f9c226727a573491"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bo8Hjfh2dBRvUB2nqV.1KQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQwNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/cd018876f2283f57f9c226727a573491","width":400,"height":230}}},{"type":"text","content":"Degenerative diseases represent some of the most common and impactful disorders globally, affecting hundreds of millions of people. Among them, demyelinating diseases, most notably Multiple Sclerosis (MS), pose a significant clinical burden. MS alone affects approximately 3 million people worldwide and increasing each year. Current therapies focus on slowing disease progression and blocking immune activity, but they do not repair existing damage. To date, no approved therapy has been found to effectively reverse myelin loss and restore neurological function, highlighting an unmet need for millions of patients.","length":617,"tagName":"p"},{"type":"text","content":"Evogene and Unravel have launched a joint effort to design and validate brain-penetrant inhibitors of a novel demyelination target discovered by Unravel's platform and create the first therapeutic designed to ...